Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
gptkb:Solexa
gptkb:Grail |
| gptkbp:collaborated_with |
gptkb:the_Human_Genome_Project
various cancer research organizations |
| gptkbp:develops |
targeted sequencing solutions
exome sequencing solutions whole genome sequencing solutions |
| gptkbp:employs |
over 7,000 people
|
| gptkbp:focuses_on |
data analysis tools
personalized medicine genetic research collaborative research |
| gptkbp:founded |
gptkb:1998
|
| gptkbp:founder |
gptkb:Jay_Flatley
|
| gptkbp:global_presence |
over 100 countries
|
| gptkbp:has_product |
pharmaceutical applications
agricultural applications clinical applications |
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Illumina Instruments
|
| gptkbp:is_committed_to |
sustainability
|
| gptkbp:is_involved_in |
research and development
clinical trials public health initiatives |
| gptkbp:is_known_for |
customer support services
high-throughput sequencing technology high accuracy in sequencing low-cost sequencing solutions |
| gptkbp:leadership |
genomic solutions
|
| gptkbp:market |
over 70% in NGS
|
| gptkbp:members |
various scientific organizations
|
| gptkbp:offers |
Next-Generation Sequencing (NGS) technology
|
| gptkbp:operates_in |
genomics
|
| gptkbp:partnerships |
various research institutions
|
| gptkbp:produced_by |
DNA sequencing systems
gene expression systems genotyping systems |
| gptkbp:product_line |
gptkb:Mi_Seq
gptkb:Nova_Seq gptkb:Next_Seq Hi Seq i Seq |
| gptkbp:provides |
bioinformatics solutions
|
| gptkbp:received |
numerous awards for innovation
|
| gptkbp:revenue |
over $3 billion (2022)
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:supports |
educational initiatives in genomics
|
| gptkbp:bfsParent |
gptkb:Illumina
|
| gptkbp:bfsLayer |
4
|